Federal Register / Vol. 65, No. 80 / Tuesday, April 25, 2000 / Notices 24227

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537. Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than (30 days from publication).

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 4374–46

(September 23, 1975), all applicants for

registration to import the basic classes

of any controlled substances in

Schedule I or II are and will continue to

be required to demonstrate to the

Deputy Assistant Administrator, Office

of Diversion Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: April 18, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–10206 Filed 4–24–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Registration

By Notice dated December 13, 1999,

and published in the Federal Register

on December 28, 1999, (64 FR 248),

Polaroid Corporation, 1265 Main Street,

Building W6, Waltham, Massachusetts

02451, made application to the Drug

Enforcement Administration (DEA) to

be registered as a bulk manufacturer of

2,5-dimethoxyamphetamine (7396), a

basic class of controlled substance listed

in Schedule I.

The firm plans to manufacture 2,5-

dimethoxyamphetamine for conversion

into a non-controlled substance.

No comments or objections have been

received. DEA has considered the

factors in title 21, United States Code,

section 823(a) and determined that the

registration of Polaroid Corporation to

manufacture 2,5-

dimethoxyamphetamine is consistent

with the public interest at this time.

DEA has investigated Polaroid

Corporation to ensure that the

company’s registration is consistent

with the public interest. The

investigation included inspection and

testing of the company’s physical

security systems, verification of the

company’s compliance with State and

local laws, and a review of the

company’s background and history.

Therefore, pursuant to 21 U.S.C. 823

and 28 CFR. 0.100 and 0.104, the

Deputy Assistant Administrator, Office

of Diversion Control, hereby orders that

the application submitted by the above

firm for registration as a bulk

manufacturer of the basic class of

controlled substance listed above is

granted.

Dated: April 6, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–10210 Filed 4–24–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Importation of Controlled Substances;

Notice of Application

Pursuant to section 1008 of the

Controlled Substances Import and

Export Act (21 U.S.C. 958(i)), the

Attorney General shall, prior to issuing

a registration under this section to a

bulk manufacturer of a controlled

substance in Schedule I or II and prior

to issuing a regulation under section

1002(a) authorizing the importation of

such a substance, provide

manufacturers holding registrations for

the bulk manufacture of the substance

an opportunity for a hearing.

Therefore, in accordance with section

1301.34 of title 21, Code of Federal

Regulations (CFR), notice is hereby

given that on January 24, 2000, Roche

Diagnostics Corporation, 9115 Hague

Road, Indianapolis, Indiana 46250,

made application to the Drug

Enforcement Administration to be

registered as an importer of the basic

classes of controlled substances listed

below:

Drug Schedule

Lysergic acid diethylamide (7315) I

Tetrahydrocannabinols (7370) ..... I

Cocaine (9041) ............................. II

Methadone (9250) ........................ II

Morphine (9300) ........................... II

The firm plans to import the listed

controlled substances for the

manufacture of diagnostic products.

Any manufacturer holding, or

applying for, registration as a bulk

manufacturer of these basic classes of

controlled substances may file written

comments on or objections to the

application described above and may, at

the same time, file a written request for

a hearing on such application in

accordance with 21 CFR 1301.43 in

such form as prescribed by 21 CFR

1316.47.

Any such comments, objections or

requests for a hearing may be addressed,

in quintuplicate, to the Deputy Assistant

Administrator, Office of Diversion

Control, Drug Enforcement

Administration, United States

Department of Justice, Washington, DC

20537, Attention: DEA Federal Register

Representative (CCR), and must be filed

no later than May 25, 2000.

This procedure is to be conducted

simultaneously with and independent

of the procedures described in 21 CFR

1301.34(b), (c), (d), (e), and (f). As noted

in a previous notice at 40 FR 43745–46

(September 23, 1975), all applicants for

registration to import the basic classes

of any controlled substances in

Schedule I or II are and will continue to

be required to demonstrate to the

Deputy Assistant Administrator, Office

of Diversion Control, Drug Enforcement

Administration that the requirements

for such registration pursuant to 21

U.S.C. 958(a), 21 U.S.C. 823(a), and 21

CFR 1301.34(a), (b), (c), (d), (e), and (f)

are satisfied.

Dated: April 6, 2000.

John H. King,

Deputy Assistant Administrator, Office of

Diversion Control, Drug Enforcement

Administration.

[FR Doc. 00–10207 Filed 4–24–00; 8:45 am]

BILLING CODE 4410–09–M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled

Substances; Notice of Application

Pursuant to section 1301.33(a) of title

21 of the Code of Federal Regulations

(CFR), this is notice that on January 24,

2000, Roche Diagnostics Corporation,

9115 Hague Road, Indianapolis, Indiana

46250, made application by renewal to

the Drug Enforcement Adminsitraiton

(DEA) for registration as a bulk

manufacturer of the basic classes of

controlled substances listed below: